REGULATORY

Review of Abortion Pill Postponed amid Flock of Public Comments

March 24, 2023
The Japanese health ministry has dropped Linepharma’s abortion pill Mefeego (mifepristone/misoprostol) from the discussion agenda of a key panel meeting for March 24, postponing its approval review due to the large number of public comments received. Mefeego was recommended for…

To read the full story

Related Article

REGULATORY

By Philip Carrigan

As the post-pandemic world of work continues to evolve, so do recruiters’ strategies and tools for finding and engaging top talent. In 2023, we are seeing these seven trends:1. Employer branding is becoming an increasingly important factor in the recruitment…

By Sakura Kono

Novo Nordisk’s weight-loss medication Wegovy (semaglutide) was approved in Japan in March. While it skipped the May round of reimbursement listing, physicians eagerly await the arrival of what would be the first new obesity drug in three decades. Other companies…

By Tatsuya Otsuka

Japan’s health ministry on April 27 presented an outline of a report to be compiled next month by its key…

A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…

Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…

Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…